BAIRD MEDICAL INVESTMENT HOL BDMD
ASignal's systematic analysis rates BDMD as Bearish.
Reflects the latest available analysis · analyzed Nov 4, 2026
The case on BDMD
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Free cash flow is strong at $22.44M, indicating solid cash generation
- High gross margin of 85.63% suggests strong pricing power
- Revenue growth of 24.6% indicates robust top-line expansion
- Low valuation metrics: P/B of 0.11x and P/S of 0.15x suggest deep value
- Negative MACD and declining momentum suggest ongoing downtrend
- Price trading significantly below SMA20 and SMA50, indicating strong bearish trend
- Negative profit margin (-65.12%) and negative ROE (-46.03%) reflect poor profitability
- EV/EBITDA of -1.66x suggests company is not generating positive EBITDA
- No Reddit mentions, indicating lack of retail investor interest
See the full verdict on BDMD
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes BDMD
Most investors never get a second opinion, let alone several. ASignal runs BDMD past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.